title: Effectiveness of medical supportive team for outpatients treated with sorafenib: a retrospective study.
abstract: BACKGROUND
  It is well known that molecular-targeted drugs, of which sorafenib (Nexavar®) is one, differ from previous anticancer drugs and cause various unusual adverse drug reactions. Treatment with sorafenib causes adverse drug reactions such as hand-foot skin reactions, hypertension, and diarrhea. Physicians spend a lot of time monitoring adverse drug reactions to sorafenib in outpatients. As such, at Okayama University Hospital, pharmacists and nurses have organized a medical supportive team to help physicians in this regard. However, the effectiveness of interventions for sorafenib-treated outpatients by this medical supportive team remains unclear. The purpose of this study was thus to clarify the effectiveness of interventions for sorafenib-treated outpatients by this medical supportive team.
  
  
  METHODS
  We retrospectively studied 70 outpatients treated with sorafenib between May 2009 and December 2012 at Okayama University Hospital. These outpatients were classified into two groups, an intervention group (31 outpatients) and a non-intervention group (39 outpatients). We compared the duration of sorafenib treatment between these groups.
  
  
  RESULTS
  The duration of treatment with sorafenib was significantly longer in the intervention group than in the non-intervention group. No outpatients in the intervention group discontinued sorafenib due to adverse drug reactions such as hand-foot skin reactions or diarrhea.
  
  
  CONCLUSIONS
  The duration of sorafenib treatment was significantly longer in the intervention group than in the non-intervention group. Our findings suggest that interventions by the medical supportive team consisting of health care professionals were effective in preventing the discontinuation of sorafenib.
authors.affiliation: Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Kajizono
authors.affiliation: Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 Japan.
authors.forename: Megumu
authors.initials: M
authors.lastname: Aoyagi
authors.affiliation: Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 Japan.
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.affiliation: Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 Japan.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Sendo
keywords: Adverse drug reactions; Hand-foot skin reactions; Hepatocellular carcinoma; Medical supportive team; Outpatient; Renal cell carcinoma; Sorafenib
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206
references.citation: Cancer Manag Res. 2012;4:423-9
references.pmid: 23293537
references.citation: J Med Case Rep. 2012 Jan 26;6:38
references.pmid: 22280970
references.citation: Eur J Cancer. 2011 Sep;47(14):2117-27
references.pmid: 21664811
references.citation: Target Oncol. 2010 Mar;5(1):59-63
references.pmid: 20309643
references.citation: J Dtsch Dermatol Ges. 2010 Sep;8(9):652-61
references.pmid: 20482685
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: J Clin Oncol. 2006 Jun 1;24(16):2505-12
references.pmid: 16636341
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Eur J Cancer. 2011 Jul;47(10):1521-6
references.pmid: 21550799
references.citation: Clin Exp Med. 2007 Dec;7(4):127-34
references.pmid: 18188524
references.citation: Lancet Oncol. 2005 Jul;6(7):491-500
references.pmid: 15992698
references.citation: Semin Oncol. 2014 Feb;41 Suppl 2:S17-28
references.pmid: 24576655
references.citation: Mol Cancer Ther. 2008 Oct;7(10 ):3129-40
references.pmid: 18852116
references.citation: Jpn J Clin Oncol. 2011 Nov;41(11):1265-70
references.pmid: 21965163
references.citation: Lancet Oncol. 2009 Jan;10(1):25-34
references.pmid: 19095497
references.citation: Int J Urol. 2010 Sep;17(9):811-5
references.pmid: 20649824
references.citation: Gan To Kagaku Ryoho. 2013 Jul;40(7):901-5
references.pmid: 23863732
references.citation: Nat Rev Drug Discov. 2006 Oct;5(10):835-44
references.pmid: 17016424
references.citation: Oncologist. 2008 Sep;13(9):1001-11
references.pmid: 18779536